Skip to main content

Table 1 Baseline characteristics of the epidemiological and clinical variables of the study population

From: Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients

Parameters

ECOG performance status

Case

N (%)

0

N (%)

≥1

N (%)

P valuea

P valueb

OR

Gender

  

 Female

125 (37.2)

64 (38.6)

61 (35.9)

   

 Male

211 (62.8)

102 (61.4)

109 (64.1)

0.612

0.699

1.10

Age (median)

  

 <60 years

165 (49.1)

90 (54.2)

75 (44.1)

   

 ≥60 years

171 (50.9)

76 (45.8)

95 (55.9)

0.064

0.126

1.37

BMI

  

 Normal

135 (40.2)

74 (44.6)

61 (35.9)

   

 Overweight

201 (59.8)

92 (55.4)

109 (64.1)

0.104

0.234

1.33

Tumor location

  

 Proximal

105 (31.3)

54 (32.5)

51 (30.0)

   

 Distal

231 (68.7)

112 (67.5)

119 (70.0)

0.617

0.885

1.11

Pathology

  

 Non-mucinous carcinoma

321 (95.5)

160 (96.4)

161 (94.7)

   

 Mucinous adenocarcinoma

15 (4.5)

6 (3.6)

9 (5.3)

0.599c

0.965

0.82

Differentiation

  

 Low grade

311 (92.6)

156 (94.0)

155 (91.2)

   

 High grade

25 (7.4)

10 (6.0)

15 (8.8)

0.328

0.185

2.51

T stage

  

 T1, 2, 3

293 (87.2)

147 (88.6)

146 (85.9)

0.464

0.568

1.08

 T4

43 (12.8)

19 (11.4)

24 (14.1)

   

N stage

  

 N 0, 1

252 (75.0)

133 (80.2)

119 (70.0)

0.032

0.088

1.67

 N 2

84 (25.0)

33 (19.9)

51 (30.0)

   

Microsatellite status

  

 MSS + MSI-L

313 (93.1)

149 (89.8)

164 (96.5)

0.035

0.024

0.30

 MSI-H

21 (6.3)

15 (9.0)

6 (3.5)

   

 Missing

2 (0.6)

2 (1.2)

0

   

KRAS

      

 Wild type

230 (68.5)

122 (73.5)

108 (63.5)

0.342

0.367

1.38

 Mutant type

81 (24.1)

38 (22.9)

43 (25.3)

   

 Missing

25 (7.4)

6 (3.6)

19 (11.2)

   

BRAF

      

 Wild type

316 (94.0)

159 (95.8)

157 (92.4 %)

0.333

0.502

0.56

 Mutant type

9 (2.7)

6 (3.6)

3 (1.8)

   

 Missing

11 (3.3)

1 (0.6)

10 (5.9)

   

TNR (median)

  

 <0.69

173 (51.5)

71 (42.8)

102 (60.0)

0.002

0.001

0.04

 ≥0.69

163 (48.5)

95 (57.2)

68 (40.0)

   
  1. BMI body mass index, ECOG Eastern Cooperative Oncology Group, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, TNR tumor to normal ratio
  2. aChi-square test
  3. bUnconditional logistic regression, adjusted for other selected covariates
  4. cFisher’s exact test
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us